Research only
All of
ALZ.ORG Research Center Alzheimer's Association International Conference ISTAART Journal Grants TrialMatch Press Donate Contact

Scientific Sessions

The schedule below reflects the invited program only. The complete schedule, including the submitted program, will be available in late spring.

Plenary Sessions Symposium Sessions
Sunday, July 24 Sunday, July 24
Monday, July 25 Monday, July 25
Tuesday, July 26 Tuesday, July 26
Wednesday, July 27 Wednesday, July 27
Thursday, July 28 Thursday, July 28


> Plenary Sessions


Sunday, July 24

10:30 - 11 a.m.

Association Welcome

Session: PL-01-01

11 - 11:30 a.m.

Preclinical to Clinical Translation for Tau Therapeutics

David Holtzman
Washington University in St. Louis,
St. Louis, Mo., United States
Session: PL-01-02

Monday, July 25

10:30 - 11 a.m.

Exercise and Memory Decline

Laura Baker
Wake Forest School of Medicine,
Winston Salem, N.C., United States
Session: PL-02-01

11 - 11:30 a.m.

Role of Peripheral Inflammation in Cognitive Impairment and Alzheimer’s Disease

Gabriela Constantin
University of Verona, Verona, Italy
Session: PL-02-02

Tuesday, July 26

10:30 - 11 a.m.

Inge Grundke-Iqbal Lecture for Alzheimer’s Research

Exosomes and Microglia in Tau Propagation

Tsuneya Ikezu
Boston University School of Medicine
Boston, Mass., United States
Session: PL-03-01

11 - 11:30 a.m.

A Moving Target? Dementia in Changing Older Populations

Carol Brayne
University of Cambridge,
Cambridge, United Kingdom
Session: PL-03-02

Wednesday, July 27

10:30 - 11 a.m.

The Science Behind Traumatic Brain Injury and Its Relationship to Dementia

Cheryl Wellington
University of British Columbia Vancouver
Vancouver, British Columbia, Canada
Session: PL-04-01

11 - 11:30 a.m.

Genomic Analysis of Neurodegeneration Gives Clues to Pathways to Selective Cell Loss: The Hypothesis of the Catastrophic Cliff of Neuron Failure

John Hardy
University College London Institute of Neurology,
London, United Kingdom
Session: PL-04-02

Thursday, July 28

10:30 - 11 a.m.

The Challenges Ahead for PET Imaging of Progressive Proteinopathies

Victor Villemagne
The Florey Institute of Neuroscience and Mental Health,
Parkville, Australia
Session: PL-05-01

11 - 11:30 a.m.

To be announced.

Session: PL-05-02


> Symposium Sessions


Sunday, July 24: 8 - 9:30 a.m.

Topic: Gender and Alzheimer’s Disease
Theme: Diagnosis and Prognosis
Session S1-01



Gender and the Genetics of Alzheimer’s Disease

M. Ilyas Kamboh
University of Pittsburgh,
Pittsburgh, Pa.,
United States

Differences Between Men and Women in the Risk of Dementia

Michelle Mielke
Mayo Clinic, Rochester,
Minn., United States

Sex-Specific Drivers of Alzheimer’s Disease Risk and Resilience

Timothy Hohman
Vanderbilt University Nashville, Tenn. United States

Sex Differences in the Brain and Implications for Alzheimer’s Disease

Gillian Einstein
University of Toronto,
Toronto, ON, Canada


Monday, July 25: 8 - 9:30 a.m.

Topic: Computerized Cognitive Training: What Works, With Whom and How?
Theme: Public Health & Psychosocial
Session: S2-01



Evidence-Based Computerized Cognitive Training: What, How, When & Where

Michael Valenzuela
University of Sydney,
South Wales, Australia

The ACTIVE Study: What We Have Learned and What is Next?

Jerri Edwards
University of South Florida,
Tampa, Fla., United States

Functional Neuroimaging in Trials of Cognition Focused Interventions

Sylvie Belleville
Institut universitaire de gériatrie de Montréal,
Montreal, QC, Canada

Unpacking Active Ingredients in Complex Cognition-focused Interventions for Older Adults at Risk of Dementia: Are Existing Classifications Still Relevant?

Alex Bahar-Fuchs
The Australian National University,
Canberra, Australia


Monday, July 25: 8 - 9:30 a.m.

Topic: Ethnic, Racial and Cultural Diversity In Dementia: Current Evidence And Projections For The Future
Theme: Public Health & Psychosocial
Session: S2-02



Brain Aging and Pathology in Older African Americans

Lisa Barnes
Rush University Medical Center,
Chicago, Ill., United States

Indigenous Australians: Lifespan, Health, Ageing and Dementia

G A (Tony) Broe
The University of New South Wales,
Sydney, Australia

Past, Present and Future of the 10/66 Dementia Research Group in Low and Middle Income Countries

Daisy Acosta
Universidad Nacional Pedro Henriquez Ureña, 
Santo Domingo, Dominican Republic

Role of Cerebrovascular Disease and Vascular Pathology on Racial Ethnic Differences in Rates of Alzheimer’s Disease and Dementia

Raj Kalaria
Newcastle University,
Newcastle, United Kingdom


Tuesday, July 26: 8 - 9:30 a.m.

Topic: What is Added Value of Biomarkers in Epidemiological Studies?
Theme: Public Health & Psychosocial
Session: S3-01



Gene Expression, Pathology and Genetic Epidemiology in Large Population-based Studies

Anita DeStefano
Boston University,
Boston, Mass., United States

Added Value of the Combined Biobank/MRI Data in the Italian Project on the Epidemiology of Alzheimer's Disease: (IPREA) Cohort

Emanuele Scafato
Istituto Superiore di Sanità,
Rome, Italy

Predicted Value of CSF/MRI Results in the Three Cities Study

Stephanie Debette University of Bordeaux,
Bordeaux, France

Prevalence of MRI Abnormalities in the Framingham Study

Charles DeCarli
University of California, Davis,
Davis, Calif., United States


Tuesday, July 26: 8 - 9:30 a.m.

Topic: Cellular and Systems Modelling of Aging and Disease
Theme: Basic and Translational Science
Session: S3-02



Modeling Circuitry and Complex Systems with Stem Cells

Rick Livesey
University of Cambridge,
Cambridge, United Kingdom

Lessons from the Midbrain

Lorenz Studer
Memorial-Sloan Kettering Cancer Center,
New York, N.Y., 
United States

iPSC Modelling of Alzheimer's Disease

Dominik Paquet
The Rockefeller University, New York, N.Y.,
United States

Modelling Microglia with Human Pluripotent Stem Cells

Sally Cowley
Oxford Stem Cell Institute,
Oxford, United Kingdom


Wednesday, July 27: 8 - 9:30 a.m.

Topic: Critical Issues in Amyloid-based Biomarkers
Theme: Diagnosis and Prognosis
Session: S4-01



Cross Sectional Studies of Plasma Proteomic Biomarkers Relating to PET Amyloid and CSF Amyloid and Tau

Alison Baird
University of Oxford,
Oxford, United Kingdom

Progress in Standardization and Implementation of CSF Biomarkers in Clinical Trials and Routine Practice

Leslie Shaw
University of Pennsylvania,
Philadelphia, Pa.,
United States

Correlation of Plasma Proteomic Biomarkers with Cerebral Amyloid in the AIBL Longitudinal Study of Aging

Ralph Martins
Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital),
Perth, Australia

CSF AD Biomarkers and Amyloid PET Imaging Give Us Similar Information in Prodromal Alzheimer’s Disease

Oskar Hansson
Lund University,
Lund, Sweden


Wednesday, July 27: 8 - 9:30 a.m.

Topic: Advances in Genetic Studies
Theme: Basic and Translational Science
Session: S4-02



Alzheimer's Disease Sequencing Project: Case-Control Analyses

Adam Naj
University of Pennsylvania,
Philadelphia, Pa.,
United States

Alzheimer's Disease Sequencing Project: Family-Based Analyses

Ellen Wijsman
University of Washington,
Seattle, Wash.,
United States

Accelerating Medicines Partnership: Co-Expression Networks

Bin Zhang
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Accelerating Medicines Partnership: Identifying Therapeutic Targets for Alzheimer’s Disease with Comparative Transcriptomic

Nilufer Ertekin-Taner
Mayo Clinic,
Jacksonville, Fla.,
United States


Thursday, July 28: 8:30 - 10 a.m.

Topic: Novel Therapeutic Approaches to Neurodegenerative Diseases
Theme: Therapeutics
Session S5-01



Macroautophagy Therapeutic Strategies for Neurodegenerative Conditions

Fiona Menzies
University of Cambridge, Cambridge, United Kingdom

Targeting of Chaperone Activity for the Treatment of Alzheimer’s Disease

Chad Dickey
University of South Florida,
Tampa, Fla., United States

Therapeutic Opportunities for the Modulation of Myeloid Cells for the Treatment of Alzheimer’s Disease

Frank Heppner
Charité - Universitätsmedizin
Berlin, Berlin, Germany

TREM2 Biology: Potential Therapeutic Targeting of Microglia for Alzheimer’s Disease Treatment

Marco Colonna
Washington University in St. Louis,
St. Louis, Mo., United States


Save on AAIC Registration with Group Rates

Bring your whole team to AAIC 2016. Discounted group rates are available for 10 or more colleagues or five or more students from the same lab group.

Where the world reveals the latest dementia research • Register now